ALYREF and neoplasm: The significant decrease in the tumor weight of Ad-PPTLS-APE1/Ref-1-injected mice at the endpoint (Figure 2D) was associated with a negligible level of luminescent tumor cells at weeks 6–12 and differed dramatically compared with the Ad-β-galactosidase-injected control groups (Figure 3A,B).